Developing a vaccination program for infectious bursal disease virus (IBDV) challenges should consider the severity and ...

Mississauga: GSK's AREXVY (respiratory syncytial virus vaccine - recombinant, AS01E adjuvanted) has been approved in Canada ...

cDepartment of Emergency Kaohsiung Municipal United Hospital, Kaohsiung City, Taiwan dDepartment of Internal Medicine Kaohsiung Municipal United Hospital, Kaohsiung City, Taiwan On Aug 14, 2024, WHO ...

According to the latest study on the subject published in The Lancet, the recent increase in cases “could be linked to a new recombinant Oropouche virus, with an increased capacity to replicate.” ...

Loopworm is ramping up production at a facility in Bangalore capable of churning out 6,000t of silkworm and black soldier fly ...

Africa has about 25.9 million (65%) of the global burden with Nigeria contributing about 1.9 million making it the fourth ...

The authors are grateful to the Council of Scientific and Industrial Research (CSIR-CCMB), India, for encouragement and support for this work. NIH Awards (R37DA025576; R01MH085259) also support SK ...

At least 24 distinct strains of the virus have been identified in Africa. However, only two strains, Types I and II, have been detected outside of the continent. In Asia, including Vietnam, only Type ...

US pharma major GSK yesterday announced new preliminary data for Arexvy (respiratory syncytial virus vaccine, recombinant ...

The virus can also reactivate as shingles ... Real-world effectiveness of recombinant zoster vaccine in self-identified Chinese individuals aged ≥50 years in the United States.